Table 2 Univariate analysis (PFS) of the pooled dataset including real-world and clinical trial patients
Variable | n | OR (95%CI) | P-value |
|---|---|---|---|
Population | |||
Trial patients | 292 | Reference | |
Real-world patients | 141 | 0.82 (0.66-1.03) | 0.088 |
Age (years) | |||
< 70 | 349 | Reference | |
≥ 70 | 84 | 1.21 (0.94-1.56) | 0.146 |
Gender | |||
Male | 225 | Reference | |
Female | 208 | 1.02 (0.83-1.25) | 0.852 |
Stage | |||
IV | 413 | Reference | |
IIIB | 20 | 0.72 (0.42-1.22) | 0.221 |
ECOG PS | |||
0 | 128 | Reference | |
1 | 298 | 1.32 (1.05-1.66) | 0.018 |
2 | 7 | 1.68 (0.78-3.62) | 0.182 |
Presence of brain metastases | |||
No | 374 | Reference | |
Yes | 59 | 0.95 (0.7-1.29) | 0.749 |
Histology tumor | |||
Adenocarcinoma | 400 | Reference | |
Large cell carcinoma | 15 | 1.18 (0.68-2.06) | 0.558 |
Adenosquamous | 3 | 1.15 (0.37-3.59) | 0.808 |
Other | 11 | 0.97 (0.48-1.97) | 0.943 |
Not otherwise specified (NOS) | 3 | 1.74 (0.56-5.44) | 0.339 |
PD-L1 expression | |||
< 1% | 141 | Reference | |
1-49% | 86 | 0.85 (0.63-1.14) | 0.272 |
> 50% | 76 | 0.53 (0.39-0.74) | < 0.001 |
Unknown | 130 | 0.93 (0.72-1.21) | 0.601 |